MARKET

VOR

VOR

Vor Biopharma Inc.
NASDAQ
17.25
+0.31
+1.83%
Pre Market: 16.99 -0.26 -1.51% 05:23 05/12 EDT
OPEN
17.13
PREV CLOSE
16.94
HIGH
18.28
LOW
17.00
VOLUME
563
TURNOVER
0
52 WEEK HIGH
65.80
52 WEEK LOW
3.064
MARKET CAP
934.70M
P/E (TTM)
-0.2447
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VOR last week (0504-0508)?
Weekly Report · 1d ago
Vor Biopharma Advances Phase 3 Telitacicept Trial in Myasthenia Gravis, Keeping Investor Focus High
TipRanks · 3d ago
Vor Bio grants 53,400 stock options at $13.85 to new hires
PUBT · 05/04 20:39
VOR BIO REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 05/04 20:30
Weekly Report: what happened at VOR last week (0427-0501)?
Weekly Report · 05/04 09:08
Vor Bio files to sell 5.34M shares of common stock for holders
TipRanks · 04/27 20:37
VOR BIOPHARMA FILES FOR RESALE OF UP TO 5.3 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 04/27 20:13
Weekly Report: what happened at VOR last week (0420-0424)?
Weekly Report · 04/27 09:09
More
About VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

Webull offers Vor Biopharma Inc stock information, including NASDAQ: VOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VOR stock methods without spending real money on the virtual paper trading platform.